Novo Nordisk Rebrands as Novo While Doubling Down on Life After Semaglutide

Novo Nordisk shares dropped 7.96% as its capital markets day promised five new blockbusters by 2030 and DKK 150bn pipeline revenue by 2035.

Novo Nordisk used its capital markets day in London on Monday to lay out a decade-long road map, but investors greeted the pitch with a sharp markdown rather than applause. Chief executive Mike Doustdar told the assembled analysts the Danish drugmaker intends to launch at least five new blockbuster medicines by 2030, a push meant to lift revenue growth toward the levels posted by big pharma peers. Management also sketched a pipeline revenue target exceeding DKK 150 billion — roughly USD 23 billion — by 2035.

The market's answer was swift. The stock shed 7.96% during Monday's session, and the shares now change hands at EUR 33.88, leaving them down 23% since the start of the year. Tuesday brought little relief, with the stock closing at EUR 33.94.

Two EMA Nods in Two Days

Away from the obesity arena, Novo picked up regulatory momentum in Europe. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of FREHEMGO on 17 September for the preventive treatment of haemophilia A in adults and children, with a European launch pencilled in for the fourth quarter of 2026. A day later, the same committee backed Sogroya for children with idiopathic short stature — a therapy that would become the first cleared for that indication in the EU if the European Commission gives its blessing.

Both recommendations bolster Doustdar's stated ambition to broaden the portfolio well beyond the company's established GLP-1 franchise.

CagriSema Delivers Head-to-Head Win

The bullish case rests on clinical evidence, and Novo brought fresh data to London. In the Phase 3 REIMAGINE 5 trial in adults with type 2 diabetes, the CagriSema combination at a dose of 1.0 mg/1.0 mg produced 12.4% weight loss after 60 weeks of treatment. Tirzepatide at 5 mg managed 9.1% over the same period. CagriSema also demonstrated non-inferior reduction in HbA1c, the key blood sugar marker.

Separately, the obesity study REDEFINE 9 showed participants losing 21% of their body weight after 68 weeks versus placebo. A US Food and Drug Administration decision on that front is expected in the fourth quarter of 2026. Should CagriSema clear its approval pathways on schedule, it could bridge the gap left by expiring patent protections on older products.

The Semaglutide Question

What unsettles shareholders is concentration. Semaglutide still underwrites the bulk of operating profit, leaving earnings exposed to regulatory intervention and mounting price pressure in key overseas markets, where discount demands are eroding margins and the pace of expansion is visibly slowing. The metric that will define the coming years is therefore simple: how much revenue new candidates can generate outside the semaglutide family.

Analysts point to muted medium-term growth and patent expiries on the semaglutide revenue driver after 2030 as persistent overhangs, compounded by intensifying competition in obesity and diabetes care. The shares sit 38% below their 52-week high, a gap that captures those structural worries.

Buybacks and a New Name

Management is leaning on capital returns as a stopgap. As of 18 September, the company had repurchased 34,174,179 of its own B shares for a total transaction value of just over DKK 9.63 billion, a programme running since February. On 14 September, Novo also announced it would unify its brand identity under the name Novo, though the official corporate designation remains Novo Nordisk A/S.

What Has to Go Right

The road ahead hinges on execution. If CagriSema and the four other planned blockbusters reach the market on time, Novo can break its reliance on legacy products and rebuild a valuation base from the current depressed level. If US price concessions bite into profits faster than new launches can compensate, even the 2035 revenue vision will struggle to arrest the downtrend. Delays in ongoing trials or unexpected hurdles at regulators would deal a heavy blow to management's growth projections and cast doubt on the 2030 targets.

The next tangible catalysts for investors are detailed study readouts and regulatory submission deadlines for CagriSema — the milestones that will show whether the promised generation of medicines can carry the business in time.